Immunological aspects of cancer chemotherapy

被引：1303

作者：

Zitvogel, Laurence ^{[1
,2
,3
]}

Apetoh, Lionel ^{[1
,3
]}

Ghiringhelli, Francois ^{[1
,2
,3
,4
]}

Kroemer, Guido ^{[3
,5
]}

机构：

[1] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France

[2] Inst Gustave Roussy, CIC BT507, F-94805 Villejuif, France

[3] Univ Paris 11, Fac Med Paris Sud, F-94276 Le Kremlin Bicetre, France

[4] Ctr Georges Francois Leclerc, F-21000 Dijon, France

[5] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France

来源：

NATURE REVIEWS IMMUNOLOGY | 2008年 / 8卷 / 01期

关键词：

D O I：

10.1038/nri2216

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Accumulating evidence indicates that the innate and adaptive immune systems make a crucial contribution to the antitumour effects of conventional chemotherapy-based and radiotherapy-based cancer treatments. Moreover, the molecular and cellular bases of the immunogenicity of cell death that is induced by cytotoxic agents are being progressively unravelled, challenging the guidelines that currently govern the development of anticancer drugs. Here, we review the immunological aspects of conventional cancer treatments and propose that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies.

引用

页码：59 / 73

页数：15

共 124 条

[41] Gaugler MH, 1997, INT J RADIAT BIOL, V72, P201, DOI 10.1080/095530097143428
[42] Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments
Ge, Q
Hu, H
Eisen, HN
Chen, JZ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) : 2989 - 2994
[43] CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
Ghiringhelli, F
Larmonier, N
Schmitt, E
Parcellier, A
Cathelin, D
Garrido, C
Chauffert, B
Solary, E
Bonnotte, B
Martin, F
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) : 336 - 344
[44] CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
Ghiringhelli, F
Ménard, C
Terme, M
Flament, C
Taieb, J
Chaput, N
Puig, PE
Novault, S
Escudier, B
Vivier, E
Lecesne, A
Robert, C
Blay, JY
Bernard, J
Caillat-Zucman, S
Freitas, A
Tursz, T
Wagner-Ballon, O
Capron, C
Vainchencker, W
Martin, F
Zitvogel, L
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (08) : 1075 - 1085
[45] Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Ghiringhelli, Francois
Menard, Cedric
Puig, Pierre Emmanuel
Ladoire, Sylvain
Roux, Stephan
Martin, Francois
Solary, Eric
Le Cesne, Axel
Zitvogel, Laurence
Chauffert, Bruno
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) : 641 - 648
[46] REGULATION OF SPECIFIC CELL-MEDIATED CYTOTOXIC RESPONSE AGAINST SV40-INDUCED TUMOR ASSOCIATED ANTIGENS BY DEPLETION OF SUPPRESSOR T-CELLS WITH CYCLOPHOSPHAMIDE IN MICE
GLASER, M
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1979, 149 (03) : 774 - 779
[47] Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer
Gomez, GG
Hutchison, RB
Kruse, CA
[J]. CANCER TREATMENT REVIEWS, 2001, 27 (06) : 375 - 402
[48] Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy
Gribben, JG
Ryan, DP
Boyajian, R
Urban, RG
Hedley, ML
Beach, K
Nealon, P
Matulonis, U
Campos, S
Gilligan, TD
Richardson, PG
Marshall, B
Neuberg, D
Nadler, LM
[J]. CLINICAL CANCER RESEARCH, 2005, 11 (12) : 4430 - 4436
[49] One hundred consecutive isolated limb perfusions with TNF-α and melphalan in melanoma patients with multiple in-transit metastases
Grünhagen, DJ
Brunstein, F
Graveland, WJ
van Geel, AN
de Wilt, JHW
Eggermont, AMM
[J]. ANNALS OF SURGERY, 2004, 240 (06) : 939 - 948
[50] HAREYAMA M, 1988, Nippon Acta Radiologica, V48, P1572

← 1 2 3 4 5 6 7 8 9 10 →